Drug Trial Radar · NCT02562482
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Nov 18, 2015
Primary completion
Mar 6, 2018
Study completion Mar 6, 2018
Sponsor
- Sponsor type
- NIH
- First posted
- Sep 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP) in healthy adults.
Conditions
- Chikungunya Virus Infection
Interventions
VRC-CHKVLP059-00-VPBiological
VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
VRC-PBSPLA043-00-VPOther
VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any InjectionTime frame: 7 days after any injection
- Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any InjectionTime frame: 7 days after any injection
- Number of Subjects With an Abnormal Laboratory ResultTime frame: 4 weeks after last injection
- Number of Subjects Reporting Unsolicited Adverse Events (AEs)Time frame: Through study completion, an average of 72 weeks after first injection
- Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 72 weeks after first injection
- Number of Subjects With Confirmed Chikungunya Virus (CHIKV) Infection EventsTime frame: Through study completion, an average of 72 weeks after first injection
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Instituto Dermatológico y Cirugía de Piel
Santo Domingo, Dominican Republic
University Hospital of Pointe-à-Pitre
Pointe-à-Pitre, Guadeloupe
Centres GHESKIO
Port-au-Prince, Haiti
Centre Hospitalier Universitaire (CHU), Martinique
Fort-de-France, Martinique
San Juan Hospital, Research Unit
Rio Piedras, Puerto Rico
Puerto Rico Clinical and Translational Research Consortium
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.